bioAffinity Technologies (NASDAQ: BIAFW) posts Reg FD investor presentation

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. furnished an investor presentation under a Regulation FD disclosure. The company plans to use these presentation materials to discuss its operations and performance, including at the H.C. Wainwright 27th Annual Global Investment Conference held from September 8–10, 2025. The presentation is attached as Exhibit 99.1 to the report and is provided for informational purposes only. It is expressly stated as being "furnished" rather than "filed," which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings.

false 0001712762 0001712762 2025-09-05 2025-09-05 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2025-09-05 2025-09-05 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2025-09-05 2025-09-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 5, 2025

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41463		46-5211056
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.007 per share		BIAF		The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase Common Stock		BIAFW		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

bioAffinity Technologies, Inc., a Delaware corporation, (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time in presentations about the Company’s operations and performance, including at the H.C. Wainwright 27^th Annual Global Investment Conference being held September 8, 2025 through September 10, 2025. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Presentation Materials – September 2025
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 5, 2025	BIOAFFINITY TECHNOLOGIES, INC.
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

FAQ

What did bioAffinity Technologies (BIAFW) report in this 8-K filing?

bioAffinity Technologies reported that it has prepared investor presentation materials about its operations and performance. These materials are being used in various presentations and are furnished as Exhibit 99.1 in the report under a Regulation FD disclosure.

Why is bioAffinity Technologies (BIAFW) furnishing presentation materials?

The company is furnishing presentation materials for use by management in discussing its business with investors and other audiences, including at the H.C. Wainwright 27th Annual Global Investment Conference in September 2025.

Are the presentation materials in the bioAffinity Technologies 8-K considered filed with the SEC?

No. The report specifies that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, under the Securities Exchange Act of 1934, which limits how it is treated for liability and incorporation purposes.

Will the bioAffinity Technologies (BIAFW) presentation be incorporated into other SEC filings?

The company states that the information in Item 7.01 and Exhibit 99.1 will not be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in those filings.

Who signed the bioAffinity Technologies 8-K related to the presentation materials?

The report was signed on behalf of bioAffinity Technologies, Inc. by Maria Zannes, who is identified as the President and Chief Executive Officer.

What exhibits are included with this bioAffinity Technologies 8-K?

The filing lists Exhibit 99.1 as the September 2025 presentation materials and Exhibit 104 as the cover page interactive data file embedded within the XBRL document.